| Trial ID: | L3348 |
| Source ID: | NCT05210517
|
| Associated Drug: |
Empagliflozin 25 Mg
|
| Title: |
SGLT2 Inhibition: Uric Acid Excretion Study
|
| Acronym: |
UREX
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Empagliflozin 25 MG|DRUG: Benzbromaron|DRUG: Empagliflozin 25 MG + benzbromarone 100 mg
|
| Outcome Measures: |
Primary: plasma uric acid, change in plasma uric acid concentrations, 1 week|Fractional uric acid excretion, change creatinine-adjusted fractional uric acid excretion, one week | Secondary: urinary glucose levels, glucose concentration urine, one week
|
| Sponsor/Collaborators: |
Sponsor: Amsterdam UMC, location VUmc
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-10-01
|
| Completion Date: |
2021-09-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-05-01
|
| Locations: |
VU University Medical Center, Amsterdam, Noord-Holland, 1081HV, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT05210517
|
